Industry Body Welcomes Publication of Life Sciences Future Skills Strategy
The UK BioIndustry Association (BIA) has issued a statement welcoming the publication of the Life Sciences 2030 Skills Strategy, a report setting out how the life sciences sector in the United Kingdom will develop future talent.
The UK BioIndustry Association (BIA) has issued a statement welcoming the publication of the Life Sciences 2030 Skills Strategy, a report setting out how the life sciences sector in the United Kingdom will develop future talent.
A key deliverable from the Life Sciences Sector Deal 2, which was updated by the UK government in 2018, this latest sector report has been created in partnership with BIA and the Association of the British Pharmaceutical Industry. The report projects that the life sciences sector of the UK will be in demand of 133,000 skilled scientific staff through to 2030.
“Developing the future talent of our sector is essential to delivering ground-breaking treatments to patients and propelling growth in a key sector of the UK economy,” said Steve Bates OBE, chief executive of BIA, in a Jan. 30, 2020 press release. “As our sector grows, we will need more specialist jobs and unique skills to deliver this crucial part of the UK Life Sciences Industrial Strategy, which will require collaboration across the eco system. BIA member companies have been powerful advocates for addressing the skills gap, providing incredible insight and evidence, and they will do all they can to support and expand the UK’s talent pipelines.”
Source: BIA
Drug Shortages and Complying with FDA’s 21 CFR 211.110 Guidance
April 2nd 2025Susan J. Schniepp, distinguished fellow at Regulatory Compliance Associates, and Rona LeBlanc-Rivera, PhD, principal consultant, Regulatory Affairs at Regulatory Compliance Associates, answer some questions about FDA’s January 2025 21 CFR 211.110 guidance document.
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
